Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT03711292
Collaborator
Los Angeles County Department of Public Health (Other), University of California, Los Angeles (Other)
143
1
1
25.8
5.5

Study Details

Study Description

Brief Summary

Stepped wedge behavioral intervention clinical trial looking at the impact of an antibiotic stewardship intervention on provider prescribing behavior for acute respiratory infections (ARIs), where the intervention is administered at the emergency department or urgent care center site level, using a cluster randomization process. Thus, every site and every provider are eligible to be exposed to the stewardship intervention, the cluster randomized stepped wedge process simply randomizes when they will be exposed. The overall study hypothesis is that providers will prescribe fewer unnecessary antibiotics to patients with ARIs after the intervention.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Antibiotic Stewardship
N/A

Detailed Description

Hypothesis: The primary hypothesis is that acute care ambulatory settings randomized to receive behavioral economic stewardship interventions will have decreased antibiotic prescribing rates for non-antibiotic appropriate ARIs, compared to contemporaneous antibiotic prescribing rates for non-antibiotic appropriate ARIs among control practices. This hypothesis will be evaluated in a linear mixed effects model will be used to estimate and test the group effect using group and time as fixed effects and practice site and provider as random effects. The interaction between time and group will be included to estimate and test the different group effect over time.

Design: The investigators will conduct a stepped wedge cluster randomized trial of acute care ambulatory visits to emergency departments and urgent care centers in a predominantly non-academic public hospital system. Clustering (by site) helps prevent treatment contamination between individual clinicians within the same site. The stepped wedge design will allow studying the effects of a complex intervention rolled out through a system over time, as often happens in the real-world, where State and Federal public health as well as site-based organization quality improvement interventions may be occurring at different times.

Treatment Assignment Procedures: For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with Centers for Disease Control and Prevention (CDC) core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
143 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Stepped wedge cluster randomized trialStepped wedge cluster randomized trial
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings
Actual Study Start Date :
Sep 7, 2018
Anticipated Primary Completion Date :
Mar 31, 2020
Anticipated Study Completion Date :
Oct 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stepped Wedge Cluster Randomized

Antibiotic stewardship intervention

Behavioral: Antibiotic Stewardship
For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.

Outcome Measures

Primary Outcome Measures

  1. Antibiotic prescribing [12 months]

    The primary outcome measure is the rate of antibiotic prescribing for non-antibiotic-appropriate acute respiratory infections or in other words, acute respiratory infections that are presumed to be viral in nature. The International Classification of Diseases (ICD)-10 codes for primary outcomes are defined in detail in the clinical trials protocol document. These outcomes are computable clinical quality measures from the electronic health record. These are widely used in medicine to evaluate quality improvement and reliability and validity are generally supported. Visits are excluded from the primary analysis when: 1) patients have certain medical co-morbidities that make ARI guidelines less likely to apply, 2) patients had concomitant visit diagnoses indicating a non-ARI possible bacterial infection, or 3) patients had concomitant visit diagnoses indicating potentially antibiotic appropriate ARI diagnoses or other ARI diagnoses suggestive of a bacterial infection.

Secondary Outcome Measures

  1. Diagnostic drift [12 months]

    Throughout the course of the study, the investigators will also be monitoring "diagnostic drift" that may result in provider shifting diagnosis to avoid guideline conflicts that might trigger poor performance reports. An auditing program will measure diagnostic deviation from each clinician's historical rates of diagnosing acute respiratory infections.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

The primary research subjects involved in this trial are prescribing providers who will be recruited from multiple clinical sites in Los Angeles County Department of Health Services.

Eligibility (provider)

Inclusion Criteria:
  • Prescribing provider in an adult emergency department or urgent care center in the Los Angeles County Department of Health Services.
Exclusion Criteria:
  • Provider has not treated a patient with an ARI

Eligibility (patient)

Inclusion Criteria:
  • Treated at a Los Angeles County Department of Health Services facility with an ARI diagnosis

  • Cared for by a provider and in practice site enrolled in the study

  • Visit occurred during the 12-month intervention period, or the 12-month historical baseline period

  • Did not have a visit with any ARI diagnosis in the prior 30 days

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Health Services Los Angeles California United States 90012

Sponsors and Collaborators

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
  • Los Angeles County Department of Public Health
  • University of California, Los Angeles

Investigators

  • Principal Investigator: Kabir Yadav, MDCM MS MSHS, University of California, Los Angeles

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
ClinicalTrials.gov Identifier:
NCT03711292
Other Study ID Numbers:
  • 31429-01
  • UL1TR001881
First Posted:
Oct 18, 2018
Last Update Posted:
Jul 2, 2019
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 2, 2019